Role of Hyaluronic Acid in the Prevention of Post-operative Adhesions: a RCT
- Registration Number
- NCT02790177
- Lead Sponsor
- Services Institute of Medical Sciences, Pakistan
- Brief Summary
- The objective of study is to determine the effect of hyaluronic acid on the formation of post-operative adhesions. It will be a randomized control trial comparing the product against normal saline. 
- Detailed Description
- Not available 
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
- All consenting patients between the ages of 12-80, who undergo exploratory laparotomy and stoma formation
Exclusion Criteria
Previous history of abdominal surgery History of peritoneal dialysis Patients in whom permanent stoma is formed
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
- Group - Intervention - Description - Normal saline - NORMAL SALINE - This group will just receive normal saline to ensure blinding. - HiB - Hyaluronic Acid - This group will receive the compound for the reduction of adhesions 
- Primary Outcome Measures
- Name - Time - Method - POST OPERATIVE ADHESIONS TO BE EVALUATED BY LAPAROSCOPY AT THREE MONTHS INTERVAL - 3 months 
- Secondary Outcome Measures
- Name - Time - Method 
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie hyaluronic acid's anti-adhesive effects in post-operative settings?
How does hyaluronic acid compare to other adhesion barriers like icodextrin in preventing post-operative adhesions?
Are there specific biomarkers that predict hyaluronic acid efficacy in post-operative adhesion prevention?
What are the long-term safety profiles of hyaluronic acid versus normal saline in abdominal surgery patients?
How do hyaluronic acid formulations compare to competitive adhesion prevention strategies in phase 3 trials?
